{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:57:50Z","timestamp":1740139070950,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12028-021-01392-0","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T16:51:52Z","timestamp":1637686312000},"page":"329-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravenous Milrinone for Cerebral Vasospasm: Here Comes the Sun?"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5311-3987","authenticated-orcid":false,"given":"Karim","family":"Lakhal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Robert-Edan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Andr\u00e9","family":"Rodie-Talbere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Ambrosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Fresco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"1392_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-021-01331-z","author":"K Lakhal","year":"2021","unstructured":"Lakhal K, Hivert A, Alexandre P-L, Fresco M, Robert-Edan V, Rodie-Talbere P-A, et al. Intravenous Milrinone for Cerebral Vasospasm in Subarachnoid Hemorrhage: the MILRISPASM controlled before-after study. Neurocrit Care. 2021. https:\/\/doi.org\/10.1007\/s12028-021-01331-z.","journal-title":"Neurocrit Care"},{"unstructured":"Mahajan C, Shukla R, Kapoor I, Prabhakar H. Intravenous milrinone for cerebral vasospasm in subarachnoid hemorrhage. Neurocrit Care (in press)","key":"1392_CR2"},{"key":"1392_CR3","first-page":"168","volume":"32","author":"LJ Velly","year":"2015","unstructured":"Velly LJ, Bilotta F, Fabregas N, Soehle M, Bruder NJ, Nathanson MH. Anaesthetic and ICU management of aneurysmal subarachnoid haemorrhage: a survey of European practice. Eur J Anaesthesiol. 2015;32:168\u201376.","journal-title":"Eur J Anaesthesiol"},{"issue":"10","key":"1392_CR4","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/CCM.0000000000003297","volume":"46","author":"J-M Mastantuono","year":"2018","unstructured":"Mastantuono J-M, Combescure C, Elia N, Tram\u00e8r MR, Lysakowski C. Transcranial Doppler in the diagnosis of cerebral vasospasm: an updated meta-analysis. Crit Care Med. 2018;46(10):1665\u201372.","journal-title":"Crit Care Med"},{"key":"1392_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12028-011-9605-9","volume":"15","author":"MN Diringer","year":"2011","unstructured":"Diringer MN, Bleck TP, Claude Hemphill J, Menon D, Shutter L, Vespa P, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society\u2019s Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15:211\u201340.","journal-title":"Neurocrit Care"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-021-01392-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-021-01392-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-021-01392-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T16:26:30Z","timestamp":1643905590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-021-01392-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1392"],"URL":"https:\/\/doi.org\/10.1007\/s12028-021-01392-0","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"type":"print","value":"1541-6933"},{"type":"electronic","value":"1556-0961"}],"subject":[],"published":{"date-parts":[[2021,11,23]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Karim Lakhal has no conflict of interest in connection with the work submitted. In addition, KL received, during the past 3\u00a0years, congress registration fees from Sanofi Aventis (once in 2018) and travel fees from MSD France (once in 2017), Gilead Sciences (once in 2017), Pfizer (three times, in 2019, 2020, and 2021), and Advanz Pharma (twice in 2020 and once in 2021). Vincent Robert-Edan has no conflict of interest in connection with the work submitted. In addition, VRE received, during the past 3\u00a0years, travel fees from Pfizer (once in 2020). None of the other authors have any financial or nonfinancial competing interests in connection with this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}